PARIS, June 23 — Antibody therapies are offering promising treatment breakthroughs for cancer and other illnesses, generating greater investor interest more than 20 years after they were first commercialised.
The treatment, Enhertu, was already authorised for breast cancer patients who had large amounts of a protein called HER2. “We hadn’t seen such progress, in terms of survival, with a chemotherapy treatment for dozens of years,” said Jacot, a professor at the Montpellier Cancer Institute in southern France.
French biotech firm Inatherys is in the first stage of clinical trials of an antibody treatment for leukaemia, its boss Pierre Launay said.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: